Pharmaceutical Partnerships with AI Drug Discovery
HealthTech Alpha, a proprietary solution by Galen Growth and the world's leading Digital Health private market data, intel, and insights platform, powers this mini report! Mini reports and Featured Flashcards can be found on HealthTech Alpha's Research page.
Highlights
Explore in this mini report the dynamic intersection between pharmaceuticals and artificial intelligence, uncovering key highlights, including Pharmaceutical partnerships with AI ventures:- AI Funding Surge: Over $13.9B invested in AI drug discovery in the last 5 years, with 2023 witnessing a monumental $6.8B surge.
- Global Collaboration: North America leads with 105 ventures, followed by Europe (80) and Asia Pacific (55), reflecting universal commitment.
- Pharma-AI Partnerships: 91 pharma giants formed 900+ partnerships; Pfizer, Bayer, and Eli Lilly at the forefront with 13 each.
- Research Focus: Cancer research dominates with 45 partnerships, showcasing industry dedication to tackling critical medical challenges.
- Pinnacle Ventures: PathAI, XtalPi, Benchling, DNAnexus, and Artios Pharma identified as mature players, leading in innovation and partnerships.
Featured Companies
The “Pharmaceutical Partnerships with AI Drug Discovery” mini report includes the following companies: Pfizer, Bayer, Lilly, Merck KGaA, Bristol-Myers Squibb, Sanofi, Johnson & Johnson Innovative Medicine, AstraZeneca, Boehringer Ingelheim, Roche, PathAI, XtalPi, Benchling, DNAnexus, Artios PharmaMissed our last report?
Get access to HealthTech Alpha and read our Pharmaceutical Digital Health Innovation Index 2023

